U.S. Markets close in 4 hrs 28 mins

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2546+0.9146 (+39.0855%)
As of 11:32AM EDT. Market open.
People also watch
  • Bought 21,400 shares of this in the premarket yesterday at $1.51. Still holding onto all the shares and extremely happy. Already up almost 30 grand
  • Today is Huge for AEZS...this is a stable company with Major growth, great financials and now positive FDA Submission News which = $$$ for the company. Soon the Upgrades and Big Name Hedge funds will start buying in now as this stock is definitely on the radar now. This stock should continue to trend up as the day goes on and even more once the upgrades start and the 1yr target increases Big Time...Baker Brothers Advisors, RA Capital and Broadfin Capital, etc. Great fundamentals, management and guidance that's in favor of share holders plus larger companies that my want to buyout AEZS.
  • it will come down still wait for it
  • NDA accepted, up big AH, should do well tomorrow. Stock doubles before the end of the year!
  • Missed US FDA approval in September last year but now sure get it by November 2017, hitting US Market with ONLY DRUG FOR AGHD approved by US FDA !!!
    Macrilen™, has been granted orphan drug designation by the FDA for diagnosis of Adult Growth Hormone Deficiency (“AGHD”). The Company owns the worldwide rights to this patented compound and has significant patent protection left. The Company’s U.S. composition of matter patent expires in 2022 and its U.S. utility patent runs through 2027. If approved, Macrilen™ will be the only FDA-approved drug indicated for use in assessing AGHD.

    The Company believes that, in the US alone, approximately 36,000 confirmatory tests for AGHD are conducted each year, which represents the target market at commercialization. Furthermore, the Company believes that Macrilen™, if it is approved, is likely to be rapidly adopted by physicians as the preferred means of evaluating AGHD for the following reasons:

    Unlike the insulin tolerance test (“ITT”), currently the most often means of evaluating AGHD, the evaluation of AGHD using Macrile™ does not require the patient to become hypoglycemic;
    Macrilen™ is administered orally, while the ITT requires an intravenous infusion of insulin;
    the evaluation of AGHD using Macrilen™ is much less time consuming and labor intensive than the ITT and, therefore, it is less expensive to conduct; and
    the evaluation can be conducted in the physician’s office rather than in a hospital setting.
    The Company intends to commercialize the product in the United States and is considering out-licensing the commercial rights in non-US territories.
  • i think i sold too early... i hope it's going to drop below $2 tomorrow at opening so i can get back in
  • it's going to open in big green tomorrow
  • 100k volume so far in pre market not bad
  • This will reach $3.00 in next an hour or two...get ready
  • pre market already up by 16% looks like very less buying chance at this price
  • Looking for $4+ tomorrow.
  • Shorts make me sick.
  • going to 2.25 for sure
  • any suggestions boutique buying in right now or wait
  • Missed AEZS then here is a much much much bigger opportunity for you ...
    KTOV = Mcap $16 Mil /Cash $17 Mil / O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20++BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets


    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.


    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • news hit the wire. secondary offered at $1.5. longs are screwed
  • Time for good business now! Money is back
  • Close at 2.34
  • Not overreacting, this is definitely going at least $3.
  • 50 million volume